Consensus CSL Limited

Stocks

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 10:40:10 16/10/2026 am IST			5-day change	1st Jan Change
192.20 ^AUD	+2.84%		+4.55%	+11.32%

14/10	EU Accepts Sanofi's Concessions to End Antitrust Probe Over Vaccine Marketing -- Update	DJ
14/10	EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing	DJ

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

de52af449434398ad1de9a07.t0RKO32U6bXKhL3Sdm71RWlOE88QmBg8bq5h0sv1BKA.-i8uaEjbh_yOtPS2NTilMCcjR6Mh6E0KAMkrnObBNNmaAAsJO9qF1qPr8A~ea147ead6ba646d3df488f25865dea30

Analysts' recommendations: CSL Limited

07/10	CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says	MT
06/10	CSL's Alentis Licensing Deal Likely to Lead to Total Addressable Market of Up to Nearly $2 Billion per Year, Jefferies Says	MT
18/08	CSL's Fiscal 2026 Results In Line, Jefferies Says	MT
25/06	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
12/05	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
20/03	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
02/03	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
11/02	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
09/12	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11/11	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
07/11	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
07/11	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
29/25/29	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
29/25/29	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
28/25/28	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
28/25/28	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
02/25/02	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
01/25/01	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
11/25/11	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
10/25/10	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
25/24/25	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
09/24/09	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
05/24/05	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
14/24/14	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
06/24/06	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSL LIMITED					+0.43%
	ELI LILLY AND COMPANY					+9.87%
	JOHNSON & JOHNSON					+9.83%
	ABBVIE INC.					-0.31%
	MERCK & CO., INC.					+7.65%
	ROCHE HOLDING AG					+1.71%
	NOVARTIS AG					+2.68%
	ASTRAZENECA PLC					+29.22%
	AMGEN INC.					-7.35%
	GILEAD SCIENCES, INC.					+3.93%
	Average					+5.77%
	Weighted average by Cap.					+6.94%